Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – A pilot study

BACKGROUND: Antibody responses to SARS-CoV-2 vaccination are impaired in people with multiple sclerosis (MS) under anti-CD20 therapies. It is however unclear, whether patients who received the basic immunization prior to anti-B cell medication start respond to the COVID-19 booster dose, once B cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Moser, Tobias, Otto, Ferdinand, O'Sullivan, Ciara, Hitzl, Wolfgang, Pilz, Georg, Harrer, Andrea, Trinka, Eugen, Wipfler, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785406/
https://www.ncbi.nlm.nih.gov/pubmed/35093840
http://dx.doi.org/10.1016/j.msard.2022.103560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785406/
https://www.ncbi.nlm.nih.gov/pubmed/35093840
http://dx.doi.org/10.1016/j.msard.2022.103560

Ejemplares similares